Glucose, beta adrenergic effects, and pancreatic endocrine function in the isolated perfused duck pancreas

Duck isolated perfused pancreas was used to assess glucose, adrenergic mediated effects and pancreatic function interrelationships. A moderate physiological 50% increase in glucose level, corresponding closely to the difference observed between 24-h-fasted and fed animals, induced a significant decrease of pancreatic glucagon not due to a rise in somatostatin secretion. The great responsiveness of the A cell was still found after glucagon stimulation by catecholamines or beta adrenergic agonism. Insulin was irresponsive to the glucose load we used, suggesting that glucose-induced glucagon suppression was also insulin independent. As far as the D cell was concerned, glucose had no effect on pancreatic somatostatin output; however, an interesting finding was that beta adrenergic agonism has a permissive effect on D cell responsiveness to the nutriment.     

Reprogramming gut and pancreas endocrine cells to treat diabetes

Multiple approaches have been investigated with the ultimate goal of providing insulin independence to patients with either type 1 or type 2 diabetes. Approaches to produce insulin-secreting cells in culture, convert non-β-cells into functional β-cells or engineer autologous cells to express and secrete insulin in a meal-responsive manner have all been described. This research has been facilitated by significant improvements in both viral and non-viral gene delivery approaches that have enabled new experimental strategies. Many studies have examined possible avenues to confer islet cytoprotection against immune rejection, inflammation and apoptosis by genetic manipulation of islet cells prior to islet transplantation. Here we review several reports based on the reprogramming of pancreas and gut endocrine cells to treat diabetes.     

The effects of thyrotropin-releasing hormone on the endocrine pancreas.

TRH has been shown to be present in the pancreas. To examine a possible role for TRH in the control of endocrine pancreatic function, we have studied the effects of TRH on the isolated perfused rat pancreas preparation. Arginine caused release of TRH from the preparation. The mean maximum TRH peak was 85 +/- 12 pg/ml and occurred later than the first phase of glucagon release. Glucagon (2000 pg/ml) did not release TRH from the preparation. There was no detectable basal release of TRH. Glucose did not stimulate release of TRH from the pancreas preparation. TRH (10 ng/ml) by itself had no effect on insulin or glucagon release. TRH enhanced arginine-induced glucagon release; mean summated glucagon was 8228 +/- 1138 (SE) pg/ml compared to controls (4530 +/- 447 pg/ml; P less than 0.01). There was a tendency for TRH to enhance second phase glucose-induced insulin release. Pancreatic physiology is in part regulated by locally acting hormones and TRH may be one of these hormones.     

Bisphenol A exerts thyroid-hormone-like effects on mouse oligodendrocyte precursor cells

We report studies on the mechanism of action of bisphenol A (BPA) on the differentiation of oligodendrocyte precursor cells (OPCs). Our results show that: (1) BPA inhibits the differentiation of OPCs induced by exposure to thyroid hormone (T3). (2) The effect is mediated through various mechanisms via the thyroid hormone receptor (TRbeta1) which is considered to be responsible for OPC differentiation. (3) The action of BPA on OPC differentiation does not involve the FcRgamma-Fyn-myelin basic protein (MBP) cascade as an inducer of OPC differentiation nor does it suppress CREB phosphorylation, which is considered to be induced by the T3-TR complex. (4) The presence of MBP isoforms (21.5, 18.5, 17.0 and 14.0 kDa) was detected in OPCs, and the expression of exon 2-containing isoforms (i.e. 17.0 and 21.5 kDa) was upregulated upon treatment with T3. In contrast, expression of MBP was inhibited by BPA.     

Phenformin has opposite effects on insulin and growth hormone binding to IM-9 lymphocytes

We studied simultaneously the effect of various concentrations of phenformin on insulin and growth hormone binding to IM-9 lymphocytes, a cell type known to have receptors for both these hormones. After 24 hr preincubation with phenformin at 2 x 10(-5) M, insulin binding to IM-9 cells was increased by 80.4 +/- 10.5% over control (mean +/- SE of 10 experiments). In parallel experiments HGH binding was decreased by 43.1 +/- 2.2% (mean +/- SE). This effect of phenformin was dose-dependent for both HGH and insulin binding over the concentration range 1.5 x 10(-6) M to 5 x 10(-5) M, and was already detectable 3 hr after phenformin addition. These data indicate that phenformin has an opposite effect on insulin and growth hormone binding to IM-9 cells. Several possible mechanisms might be suggested for the decrease of HGH binding sites induced by phenformin: the simultaneous opposite effect on HGH and insulin receptors raises the possibility that some metabolic event triggered by the drug is able to induce opposite changes in the binding of these two hormones with different biological activities.     

1,25-Dihydroxyvitamin D3 exerts opposite effects on the regulation of human embryonic and nonembryonic alkaline phosphatase isoenzymes

The regulation of alkaline phosphatase activity by steroid hormones was studied in two human breast cancer cell lines, MDA-MB-157 and BT20. MDA-MB-157 cells were shown to express the alkaline phosphatase isoenzyme produced by normal breast tissue, and the activity of this isoenzyme increased 3-fold after a 72-h treatment of these cells with 10(-7) M 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], 2-fold after treatment with 10(-6) M hydrocortisone (HC), and 5-fold after treatment with both hormones. BT20 cells did not express the isoenzyme phenotypic to breast, but ectopically expressed the isoenzyme phenotypic to term placenta and other embryonic tissue. Treatment of BT20 cells with 1,25-(OH)2D3 results in a 30% decrease in alkaline phosphatase activity of the embryonic isoenzyme. There was a 2-fold increase in activity after treatment with HC, and enzyme activity was similar to control values after treatment with both hormones. For both cell lines, changes in alkaline phosphatase activity correlated with changes in nanograms of isoenzyme per mg cellular protein, as measured by RIA. Increases in enzyme activity were inhibited when the cells were incubated simultaneously with the steroids and cycloheximide. Studies with receptors in each cell line showed that both cell lines bound 1,25-(OH)2D3 and that a 1,25-(OH)2D3-binding protein with the same mol wt as the D3 receptor was present in both. The BT20 cells also express a larger mol wt protein which binds 1,25-(OH)2D3 but is not as specific for the 1,25-(OH)2D3 isomer. HC receptors were similar in quantity and binding affinity in both cell lines.     

Morphological localisation of sulfonylurea receptor 1 in endocrine cells of human,mouse and rat pancreas

Aims/hypothesis Sulfonylurea receptor 1 (SUR1) is the regulatory subunit of ATP-sensitive K channels in beta cells. Morphological methods (immunohistochemistry and sulfonylurea binding) were used to establish the cellular and subcellular location of SUR1 in human and rodent islets. Results In the human, mouse and rat pancreas, all endocrine cells of the islets were immunolabelled with an anti-SUR1 antibody, whereas tissues containing SUR2 were consistently negative, as were those from Sur1 (also known as Abcc8)^−/− mice. In beta cells of the three species, the plasma membrane was distinctly stained, but SUR1 was mainly present over the cytoplasm, with an intensity that varied between cells. Electron microscopy showed that SUR1 was immunolocalised in insulin, glucagon and somatostatin granules. In rat beta cells degranulated by in vivo treatment with glibenclamide (known as glyburide in the USA and Canada), the insulin and SUR1 staining intensity was similarly decreased by ∼45%, whereas SUR1 staining was not changed in non-beta cells. In all islet cells, binding of glibenclamide labelled with fluorescent dipyrromethane boron difluoride (BODIPY-FL) was punctate over the cytoplasm, compatible with the labelling of endocrine granules. A faint labelling persisted in Sur1 ^−/− mice, but it was not different from that obtained with BODIPY-FL alone used as negative control. Conclusions/interpretation Our study immunolocalised SUR1 in alpha, beta and delta cells of human, mouse and rat islets, and for the first time visualised it in the plasma membrane. We also show that SUR1 is abundant in endocrine granules, where its function remains to be established. No specific sulfonylurea-binding sites other than SUR1 are identified in islet cells by the glibenclamide–BODIPY-FL technique.     

Glucose loading during primary culture has opposite effects on the viability of hepatocytes exposed to potassium cyanide and to iodoacetic acid

Whether or not to apply nutritional pretreatment and how to do so are controversial issues with respect to the liver about to undergo aggressive intervention. We studied the effects of glucose loading on the viability of hepatocytes that were subsequently exposed to the inhibitors of carbohydrate metabolism, potassium cyanide (KCN) and iodoacetic acid (IAA). After rat hepatocytes were cultured for 24 hours in Leibovitz's L-15 medium containing 0, 10, 20, and 30 mmol/L glucose, the medium was replaced with modified Hanks-HEPES buffer with or without 2.5 mmol/L KCN or 0.5 mmol/L IAA. Lactate dehydrogenase (LDH) activity, lactate concentration, and pH of the supernatant were measured after 0, 2, 4, and 6 hours of exposure to KCN and after 0, 20, 40, and 60 minutes of exposure to IAA. Glycogen and adenosine triphosphate (ATP) contents in the hepatocytes were measured simultaneously. Hepatocytes cultured with various concentrations of glucose for 24 hours stored levels of glycogen in proportion to the glucose concentration in the culture medium without any significant difference in viability. The hepatocytes cultured with higher glucose concentrations maintained a higher ATP content and released less LDH and more lactate, and the pH decreased in the supernatant during exposure to KCN. Conversely, hepatocytes cultured with lower glucose concentrations maintained a higher ATP content and released less LDH during exposure to IAA. In conclusion, prior glucose loading appears to be beneficial for hepatocytes if oxidative phosphorylation is to be inhibited, whereas withholding glucose appears to be beneficial if glycolysis is to be inhibited.     

Inhibition of hypothalamic and pituitary muscarinic receptor binding by progesterone

The in vitro effects of estrogens, progestins, and their related analogs on muscarinic receptor binding sites were studied in the hypothalamic membranes prepared from ovariectomized rats. The binding assays were performed under a nonequilibrium condition. Progestins and their metabolites were active in inhibiting the binding of [3H](-)QNB to muscarinic receptors, whereas estrogenic compounds were devoid of this effect. Progesterone was also found to be active in inhibiting the binding of [3H](-)QNB to pituitary membranes. The IC50 values of progesterone and its metabolite, 17 alpha-hydroxyprogesterone, were 34 and 24 microM, respectively. The inhibitory effect of progesterone was rapid, reversible, and not dependent on divalent metal ions (Ca2+, Cu2+, Fe2+, Mg2+, Mn2+, and Zn2+). Analyses of the binding data with Scatchard and Lineweaver-Burke plots revealed that progesterone significantly increased the apparent Kd of muscarinic receptor binding sites from 0.54 (SE = +/- 0.08) nM to 2.44 (SE = +/- 0.49) nM in hypothalamic membranes and from 0.21 (SE = +/- 0.03) nM to 0.34 (SE = +/- 0.03) nM in pituitary membranes without a significant effect on the receptor density in both membrane preparations. Progesterone decreased the rate of association of [3H](-)QNB with muscarinic receptors without a significant effect on its rate of dissociation from the [3H](-)QNB-receptor complex. These results indicate that progesterone, but not estrogenic compounds, was capable of interacting with hypothalamic and pituitary muscarinic receptors in vitro.     

APUD cells in the endocrine pancreas and the intestine of chick embryos

Formaldehyde-induced fluorescence has demonstrated biogenic amine-storing (APUD) cells in the duodenum of chick embryos from day 13 or 14 of incubation. These are definitive intestinal endocrine cells. If DOPA was administered to the embryos, a few cells were fluorescent only 1 day sooner. Following DOPA-treatment, fluorescence revealed cells with biogenic amine-synthesizing ability (also APUD cells) scattered in the gut groove at 16- to 18-somite stages, concentrated at the site of imminent evagination of the dorsal pancreatic bud later on, then localized within the bud in groups, and later grouped and scattered in the pancreas. In the absence of exogenous DOPA, their fluorescence was evident by day 13 or 14 only. It seems probable that the APUD cells scattered in the gut at early stages are the precursors of islet cells of one or more than one type.     

Stimulatory and inhibitory effects of galanin on exocrine and endocrine rat pancreas.

The influence of the neuropeptide galanin, present in intrapancreatic nerve endings, on the endocrine pancreas is well known. The most potent effect of galanin is inhibition of insulin release. Little is known of its effect on the exocrine pancreas. Whether galanin plays a role in the regulation of exocrine pancreatic secretion and whether this effect is mediated directly on acinar cells or indirectly via the influence on insulin secretion is not clear. In the present study, we investigated these questions using the model of the isolated and arterially perfused rat pancreas with intact exocrine and endocrine secretion. In the presence of 15.8 mM glucose in a modified Krebs-Ringer buffer and during half-maximal stimulation of enzyme secretion with 100 pmol/ml cholecystokinin octapeptide (CCK-8), a dose-response study of 0.001-100 pmol/ml porcine galanin was performed. At concentrations of 0.001 and 0.01 pmol/ml, porcine galanin significantly stimulated insulin release (p < 0.05 and < 0.01, respectively) and also significantly enhanced CCK-8-stimulated amylase secretion (p < 0.05). Doses of 0.1 and 1 pmol/ml galanin resulted in a nonsignificant inhibition of insulin release, while 10 and 100 pmol/ml strongly inhibited the endocrine response (p < 0.001). However, concentration levels of 1-100 pmol/ml galanin did not affect CCK-8-stimulated amylase secretion. Rat galanin, tested at 0.01 and 10 pmol/ml, showed no significant difference from the effects of porcine galanin at the equipotent concentrations. It is concluded that the effect of galanin on exocrine pancreas, like the effect on endocrine functions, tends to be a direct one and that it could exert a modulatory influence on the level of neuronal transmission.     

Inhibitory effects of pirenzepine on cholecystokinin and secretin stimulation on exocrine and endocrine rat pancreas

Effects of pirenzepine, a newly developed anticholinergic drug, on exocrine and endocrine pancreatic functions stimulated by cholecystokinin octapeptide and secretin were studied in both isolated pancreatic acini and the isolated perfused pancreas of rats. In the isolated acini, pirenzepine did not have any significant effect on cholecystokinin-inducec amylase release but caused an inhibition of amylase secretion initiated by secretin and shifted the dose-response curve for amylase secretion to the right. In the isolated perfused pancreas stimulated with 100 pM cholecystokinin octapeptide, addition of 10 M pirenzepine before as well as after 20 min of perfusion significantly inhibited pancreatic juice flow but not enzyme output. In contrast, pirenzepine caused an inhibition of secretin-stimulated enzyme secretion, but not pancreatic juice flow. The stimulatory effect of both cholecystokinin octapeptide and secretin on insulin secretion was also inhibited by pirenzepine. The present data indicate that pirenzepine may have an influence on pancreatic exocrine and endocrine function by inhibiting endogenous cholinergic activity of the pancreas when a large dose is given.     

Reciprocal modulation of agonist and antagonist binding to muscarinic cholinergic receptor by guanine nucleotide.

The ability of guanine nucleotide to decrease the binding affinity of agonists but not antagonists has been documented in a number of hormone and neurotransmitter receptor systems. By contrast, recent reports indicate that both agonist and antagonist binding to the muscarinic cholinergic receptors appear to be regulated in a reciprocal fashion by guanine nucleotide. We document two forms of the muscarinic cholinergic receptor in frog heart, which are present in approximately equal proportions and which display high-agonist/low antagonist and low-agonist/high-antagonist affinities, respectively. Guanine nucleotide appears to convert the former type of site into the latter type. These observations can be interpreted in terms of a model for two interconvertible forms of the muscarinic cholinergic receptor reciprocally favored by agonists and antagonists. This model has implications both for the understanding of neurotransmitter-receptor interactions generally and for the nature of the biological effects of receptor antagonists.     

Effects of treatment with progesterone and oestradiol-17 beta on the endocrine pancreas in ovariectomized rats: ultrastructural variations in the B cells

The effects of progesterone and/or oestradiol treatment on the ultrastructural appearance of the pancreatic B cells has been studied in ovariectomized Wistar rats. A morphometric examination of the numberical density of dark and high granules in the B cells was therefore performed in each group of experimental rats as well as in control (olive oil-injected) rats. In the oestradiol-treated rats, and especially in the rats with combined oestradiol/progesterone treatment, the proportions of light and dark granules in the pancreatic B cells changed, compared with control values, in favour of the light granules. This increase in light granule content was comparable to changes in B cells during a pregnancy and it is suggested that the secretory activity of the B cells increases during pregnancy in a manner similar to that seen during oestradiol treatment.     

Topographical associations between islet endocrine cells and duct epithelial cells in the adult human pancreas

Objectives  The pancreatic ducts, endocrine islets and exocrine acini are three functionally related components. From birth to adulthood, the islets and ducts are regarded as independent entities. The objective of this study is to investigate the topographical associations between the islet endocrine cells and duct epithelial cells in the adult human pancreas.
Materials and methods  Panels of immunomarkers for the exocrine acinar cells (amylase), duct cells [cytokeratin 19 (CK19)], endocrine cells (chromogranin A, neurone specific enolase, synaptophysin) and islet hormones (glucagon, insulin, somatostatin, pancreatic polypeptide) were applied to sequential pancreatic tissue sections obtained from autopsy specimens of 10-nondiabetic human adults. Double immunofluorescent staining with CK19 and islet hormones was performed to confirm the islet to duct interrelationship.
Results  Sequential sectioning and immunostaining showed that 45% of the 172 islets examined appeared as single endocrine cell units or small clusters of < 10 endocrine cells on at least one plane of section. A topographical association was found between the islet endocrine cells and duct epithelial cells. Topographical associations with CK 19-stained duct cells occurred in 10·9% of the islet insulin-containing β-cells and in 8·9% of the islet glucagon-producing α-cells. The frequency of topographical associations increased toward the more distally located duct systems. The CK19-stained duct cells and amylase-labelled acinar cells were less frequently in association with other islet hormone-producing cells.
Conclusions  Topographical associations between islet endocrine cells and pancreatic duct cells are frequent in adult human pancreas. The islet–duct association suggests possible functional interactions between the two interrelated pancreatic compartments.     

Development,differentiation and derivation of the endocrine polypeptide cells of the mouse pancreas

Summary Studies on the developing mouse pancreas indicate that neuroectodermal cells from the neural crest, identifiable by their APUD-FIF characteristics, colonize the foregut at around the 10th day. Carried into the pancreatic anlagen, their primitive pleomorphic granules are progressively replaced by spherical granules which are ultimately (around 16 days) identifiable as of A, B or D type. — Insulin and glucagon are first demonstrable, by immunofluuorescence, at the 14th day, at which time zymogen granules are detectable by electron microscopy. — It is postulated that the neuroectodermal cell of the neural crest may be the precursor of some or all of the three known endocrine cells of the pancreatic islets. In the case of the A and D cells present evidence is considered sufficiently strong to make this a tenable hypothesis.Supported by Grants from the Wellcome Trust and the Cancer Campaign (CMH).